All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

Disease AreasTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2024-11-06T15:45:04.000Z

Upcoming congress abstracts: What’s hot in psoriasis and psoriatic arthritis?

By Ella Dixon
Featured
Alice Gottlieb
André Carvalho
Joseph Merola
Laura Coates
Paolo Gisondi
Peter Nash
Ulrich Mrowietz
Yukari Okubo
Nov 6, 2024
Share:

To help navigate the exciting content being presented at an upcoming rheumatology congress, the PsOPsA Hub Steering Committee have provided their recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

 Psoriasis

Abstract

Title

0303

Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

1131

Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

1135

Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials

1137

Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)

2348

Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension



Psoriatic arthritis

Abstract

Title

0582

Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

0600

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies

0601

Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib

0602

Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration

1457

Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial

1464

Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study

1466

Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial

1477

Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study


Rheumatology congress 2024 top abstracts

To download this document, click below.

Download here


More about...
PsoriasisPsoriatic arthritis

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
10 votes - 49 days left ...

Related articles

Add bookmark

EULAR 2024: Top abstracts in psoriasis and psoriatic arthritis

To help navigate the exciting content being presented at EULAR 2024, we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

Jun 11, 2024
Add bookmark

EULAR 2024: Top abstracts in psoriasis and psoriatic arthritis

To help navigate the exciting content being presented at EULAR 2024, we have provided recommendations for the top abstracts to look out...

Jun 11, 2024
Add bookmark

What does the current treatment landscape look like in psoriasis and PsA?

During the Psoriasis Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss the current treatment landscape for patients with psoriasis and PsA.

Feb 2, 2024
Add bookmark

What does the current treatment landscape look like in psoriasis and PsA?

During the Psoriasis Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss the current treatment...

Feb 2, 2024

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox